Merck Receives Positive EU CHMP Opinion for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal ...

The European Medicines Agency (EMA) has recommended granting marketing authorization for the pneumococcal vaccine Capvaxive (pneumococcal polysaccharide conjugate vaccine [21-valent]) intended to ...

Drug major Merck & Co. (MRK) announced Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use or ...

As of 9:17 a.m. on this day, SK bioscience is trading at 53,400 won, which is an increase of 3,900 won (7.88%) compared to ...

SK bioscience and Sanofi have announced plans for global Phase III studies, which will assess the safety and immunogenicity ...

The ACIP-approved immunization schedules for children and adolescents and for adults for 2025 have been published.

Expert Rev Vaccines. 2009;8(8):1051-1061. Simply defined as an extension of the benefit of protection from immunization in those immunized to those unimmunized in a community, herd effect was key ...

The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended four novel medicines for approval at its ...

Merck (NYSE:MRK) has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for ...

In India, the prevalence of chronic kidney disease (CKD) has reached epidemic proportions, with population-based studies ...

Merck on Friday said the recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use covers the 21-valent conjugate vaccine for immunization for the prevention ...

PCV21 is the first pneumococcal conjugate vaccine candidate with more than 20 serotypes to enter a Phase III clinical trial in infants and toddlers. Sanofi and SK Bioscience announced that they have ...